Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Insights into Irritable Bowel Syndrome
share announcement

New Insights into Irritable Bowel Syndrome

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 26 April 2025 | Viewed by 2337

Special Issue Editors

Dr. Pierfrancesco Visaggi

E-Mail Website
Guest Editor
Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
Interests: disorders of gut-brain interaction; irritable bowel syndrome; eosinophilic gastrointestinal disorders; diarrhoea; abdominal pain; high-resolution manometry
Prof. Dr. Massimo Bellini

E-Mail Website
Guest Editor
Gastrointestinal Unit, Department of Translational Sciences and New Technology in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy
Interests: disorders of gut-brain interaction; irritable bowel syndrome; FODMAPs; low-FODMAPs diet; anorectal manometry; chronic constipation; functional dyspepsia; gastroparesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disease that represents a significant cause of morbidity worldwide. The disease significantly affects patients’ quality of life, work productivity and social functioning. The pathophysiology of IBS is not completely understood and its diagnosis should be made based on the Rome IV criteria. Nevertheless, the severity of the patient’s symptoms and concerns sometimes drives the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. Therefore, a deeper knowledge of IBS mechanisms is mandatory to improve the management of the disease. Conventional treatments include lifestyle changes, diets, probiotics, laxatives, antidiarrhoeals and antispasmodics. More recently, other therapies have been investigated in randomized controlled trials and observational studies, including faecal microbiota transplantation, central neuromodulators, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, minimally absorbed antibiotics, and psychological therapies.

The scientific community will certainly benefit from updated reviews focusing on the optimal management of IBS. In this Special Issue, we invite you to submit your updated review addressing the management aspects and/or therapeutics of IBS.

We look forward to your contribution relating to this cutting-edge Special Issue of the Journal of Clinical Medicine.

Dr. Pierfrancesco Visaggi
Prof. Dr. Massimo Bellini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • irritable bowel syndrome
  • management
  • disorders of gut–brain interactions
  • neuromodulators
  • fecal microbiota
  • probiotics
  • diet
  • FODMAPs
  • intestinal secretagogues
  • 5-HT receptors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 457 KiB  
Review
A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence
by Anthony J. Papale, Robert Flattau, Nandan Vithlani, Deepti Mahajan and Sandeep Nadella
J. Clin. Med. 2024, 13(22), 6948; https://doi.org/10.3390/jcm13226948 - 18 Nov 2024
Viewed by 575
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent and debilitating disorder of gut–brain interaction (DGBI) affecting millions globally. It imposes a significant burden on healthcare systems and is a leading cause of workplace absenteeism. IBS is classified into several subtypes based on predominant [...] Read more.
Irritable bowel syndrome (IBS) is a highly prevalent and debilitating disorder of gut–brain interaction (DGBI) affecting millions globally. It imposes a significant burden on healthcare systems and is a leading cause of workplace absenteeism. IBS is classified into several subtypes based on predominant presenting symptoms, including IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), with each requiring targeted approaches to treatment. Some treatments, such as psychotherapy, dietary intervention, and medications like tricyclic antidepressants, are nonspecific and recommended for managing IBS symptoms across all subtypes. In contrast, therapies like secretagogues for IBS-C and eluxadoline or rifaximin for IBS-D are subtype-specific. However, many IBS treatments carry conditional recommendations and are based on low-certainty evidence, emphasizing the need for further research to expand the available treatment options. This review compares the latest IBS management guidelines from the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), British Society of Gastroenterology (BSG), and European Society for Neurogastroenterology and Motility (ESNM). Pharmacologic and non-pharmacologic therapies, including established and emerging interventions, will be explored to provide a comprehensive guide to management. Full article
(This article belongs to the Special Issue New Insights into Irritable Bowel Syndrome)
►▼ Show Figures

Figure 1

17 pages, 1038 KiB  
Review
The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome
by Vlad Alexandru Ionescu, Gina Gheorghe, Teodor Florin Georgescu, Nicolae Bacalbasa, Florentina Gheorghe and Camelia Cristina Diaconu
J. Clin. Med. 2024, 13(17), 5124; https://doi.org/10.3390/jcm13175124 - 29 Aug 2024
Viewed by 1426
Abstract
Globally, irritable bowel syndrome (IBS) is present in approximately 10% of the population. While this condition does not pose a risk of complications, it has a substantial impact on the patient’s quality of life. Moreover, this disease has a significant financial impact on [...] Read more.
Globally, irritable bowel syndrome (IBS) is present in approximately 10% of the population. While this condition does not pose a risk of complications, it has a substantial impact on the patient’s quality of life. Moreover, this disease has a significant financial impact on healthcare systems. This includes the direct costs associated with the diagnosis and treatment of these patients, as well as the indirect costs that arise from work absenteeism and reduced productivity. In light of these data, recent research has focused on elucidating the pathophysiological basis of this condition in order to improve the quality of life for affected individuals. Despite extensive research to date, we still do not fully understand the precise mechanisms underlying IBS. Numerous studies have demonstrated the involvement of the gut–brain axis, visceral hypersensitivity, gastrointestinal dysmotility, gut microbiota dysbiosis, food allergies and intolerances, low-grade mucosal inflammation, genetic factors, and psychosocial factors. The acquisition of new data is crucial for the advancement of optimal therapeutic approaches aimed at enhancing the general health of these patients while simultaneously reducing the financial burden associated with this ailment. Full article
(This article belongs to the Special Issue New Insights into Irritable Bowel Syndrome)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics and short chain fructooligosaccharides in patients with irritable bowel syndrome – a randomized, double-blind, placebo-controlled study
Author: Cukrowska
Highlights: 1. The first randomized placebo-controlled clinical trial presenting the efficacy and safety of microencapsulated sodium butyrate with the mixture of Lactobacillus and Bifidobacterium strains along with short-chain fructooligosaccharides in IBS adult patients. 2. The biotic preparation supplementation induced both statistically significant relief and reduction of worsening in IBS symptoms evalueted with IBS-AR and IBS-GIS scales, respectively.

Back to TopTop